S&P 500   5,072.85 (+0.22%)
DOW   37,937.90 (+0.54%)
QQQ   432.57 (+0.35%)
AAPL   169.67 (-1.75%)
MSFT   416.22 (+0.62%)
META   501.57 (+0.27%)
GOOGL   154.94 (+0.05%)
AMZN   183.81 (+0.10%)
TSLA   156.61 (-3.02%)
NVDA   877.45 (+2.03%)
AMD   163.57 (+2.03%)
NIO   3.85 (-1.03%)
BABA   69.96 (-0.93%)
T   16.04 (-1.23%)
F   12.18 (-0.41%)
MU   121.98 (+0.50%)
GE   156.75 (+1.98%)
CGC   6.80 (-2.58%)
DIS   114.03 (+0.96%)
AMC   2.78 (+12.55%)
PFE   25.80 (-0.42%)
PYPL   63.76 (+0.39%)
XOM   119.17 (-0.43%)
S&P 500   5,072.85 (+0.22%)
DOW   37,937.90 (+0.54%)
QQQ   432.57 (+0.35%)
AAPL   169.67 (-1.75%)
MSFT   416.22 (+0.62%)
META   501.57 (+0.27%)
GOOGL   154.94 (+0.05%)
AMZN   183.81 (+0.10%)
TSLA   156.61 (-3.02%)
NVDA   877.45 (+2.03%)
AMD   163.57 (+2.03%)
NIO   3.85 (-1.03%)
BABA   69.96 (-0.93%)
T   16.04 (-1.23%)
F   12.18 (-0.41%)
MU   121.98 (+0.50%)
GE   156.75 (+1.98%)
CGC   6.80 (-2.58%)
DIS   114.03 (+0.96%)
AMC   2.78 (+12.55%)
PFE   25.80 (-0.42%)
PYPL   63.76 (+0.39%)
XOM   119.17 (-0.43%)
S&P 500   5,072.85 (+0.22%)
DOW   37,937.90 (+0.54%)
QQQ   432.57 (+0.35%)
AAPL   169.67 (-1.75%)
MSFT   416.22 (+0.62%)
META   501.57 (+0.27%)
GOOGL   154.94 (+0.05%)
AMZN   183.81 (+0.10%)
TSLA   156.61 (-3.02%)
NVDA   877.45 (+2.03%)
AMD   163.57 (+2.03%)
NIO   3.85 (-1.03%)
BABA   69.96 (-0.93%)
T   16.04 (-1.23%)
F   12.18 (-0.41%)
MU   121.98 (+0.50%)
GE   156.75 (+1.98%)
CGC   6.80 (-2.58%)
DIS   114.03 (+0.96%)
AMC   2.78 (+12.55%)
PFE   25.80 (-0.42%)
PYPL   63.76 (+0.39%)
XOM   119.17 (-0.43%)
S&P 500   5,072.85 (+0.22%)
DOW   37,937.90 (+0.54%)
QQQ   432.57 (+0.35%)
AAPL   169.67 (-1.75%)
MSFT   416.22 (+0.62%)
META   501.57 (+0.27%)
GOOGL   154.94 (+0.05%)
AMZN   183.81 (+0.10%)
TSLA   156.61 (-3.02%)
NVDA   877.45 (+2.03%)
AMD   163.57 (+2.03%)
NIO   3.85 (-1.03%)
BABA   69.96 (-0.93%)
T   16.04 (-1.23%)
F   12.18 (-0.41%)
MU   121.98 (+0.50%)
GE   156.75 (+1.98%)
CGC   6.80 (-2.58%)
DIS   114.03 (+0.96%)
AMC   2.78 (+12.55%)
PFE   25.80 (-0.42%)
PYPL   63.76 (+0.39%)
XOM   119.17 (-0.43%)
Free Trial

Revance Therapeutics (RVNC) Earnings Date, Estimates & Call Transcripts

→ Can't believe it's happening again (From Manward Press) (Ad)
Free RVNC Stock Alerts
$3.86
-0.11 (-2.77%)
(As of 03:21 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
May. 14Estimated
Actual EPS
(Feb. 28)
-$0.62 Beat By $0.17
Consensus EPS
(Feb. 28)
-$0.79
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

RVNC Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RVNC Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Revance Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242($0.69)($0.56)($0.63)
Q2 20242($0.59)($0.56)($0.58)
Q3 20242($0.66)($0.49)($0.58)
Q4 20242($0.55)($0.43)($0.49)
FY 20248($2.49)($2.04)($2.27)
Q1 20251($0.49)($0.49)($0.49)
Q2 20251($0.26)($0.26)($0.26)
Q3 20251($0.26)($0.26)($0.26)
Q4 20251($0.20)($0.20)($0.20)
FY 20254($1.21)($1.21)($1.21)

RVNC Earnings Date and Information

Revance Therapeutics last announced its quarterly earnings data on February 28th, 2024. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.17. The company had revenue of $69.80 million for the quarter, compared to the consensus estimate of $64.02 million. Revance Therapeutics has generated ($3.79) earnings per share over the last year (($3.79) diluted earnings per share). Earnings for Revance Therapeutics are expected to grow in the coming year, from ($2.17) to ($1.13) per share. Revance Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off prior year's report dates.

Revance Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/14/2024
Estimated)		------- 
2/28/2024Q4 2023($0.79)($0.62)+$0.17($0.62)$64.02 million$69.80 million    
11/8/2023Q3 2023($1.02)($0.74)+$0.28$0.15$58.49 million$56.78 million
8/8/2023Q2 2023($0.72)($0.80)($0.08)($0.80)$58.71 million$58.13 million    
5/9/2023Q1 2023($0.75)($0.74)+$0.01($0.74)$46.21 million$49.33 million      
2/28/2023Q4 2022($1.04)($1.82)($0.78)($1.82)$45.10 million$49.90 million      
11/8/2022Q3 2022($0.85)($1.17)($0.32)($1.17)$28.76 million$29.02 million
8/9/2022Q2 2022($0.91)($0.88)+$0.03($0.88)$27.64 million$28.37 million
5/10/2022Q1 2022($0.91)($0.94)($0.03)($0.94)$23.55 million$25.26 million
2/28/2022Q4 2021($0.98)($0.93)+$0.05($0.93)$24.56 million$25.95 million    
11/9/2021Q3 2021($1.15)($1.10)+$0.05($1.10)$20.03 million$19.75 million    
8/5/2021Q2 2021($1.14)($1.07)+$0.07($1.07)$16.68 million$18.80 million
5/10/2021Q1 2021($1.19)($1.08)+$0.11($1.08)$12.44 million$13.30 million    

Revance Therapeutics Earnings - Frequently Asked Questions

When is Revance Therapeutics's earnings date?

Revance Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off last year's report dates. Learn more on RVNC's earnings history.

Did Revance Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Revance Therapeutics (NASDAQ:RVNC) reported ($0.62) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.79) by $0.17. Learn more on analysts' earnings estimate vs. RVNC's actual earnings.

How can I listen to Revance Therapeutics's earnings conference call?

The conference call for Revance Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Revance Therapeutics's conference call transcript?

The conference call transcript for Revance Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Revance Therapeutics generate each year?

Revance Therapeutics (NASDAQ:RVNC) has a recorded annual revenue of $234.04 million.

How much profit does Revance Therapeutics generate each year?

Revance Therapeutics (NASDAQ:RVNC) has a recorded net income of -$323.99 million. RVNC has generated -$3.79 earnings per share over the last four quarters.

What is Revance Therapeutics's EPS forecast for next year?

Revance Therapeutics's earnings are expected to grow from ($2.17) per share to ($1.13) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:RVNC) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Biden to Launch “FedNOW” [Move Your Money Now]
Priority Gold
Can't believe it's happening again
Manward Press
Your eBook: Mastering Earnings Announcements Trading
StockEarnings
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
The “Perfect Storm” for Gold
Gold Safe Exchange
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
The Greatest Bull Market in Crypto History…
Weiss Ratings